Prima Biomed Ltd., of Sydney, said it expects the first patient in a phase IIb study of its lead compound, IMP321 (LAG-3Ig fusion protein), will be dosed early next year. The AIPAC (Active Immunotherapy PAClitaxel) study is a multicenter, randomized, double-blind, placebo-controlled trial in hormone receptor-positive metastatic breast carcinoma patients. Read More

In a way, it was a back to the base-ics year for scientific advances. Two of the biggest science stories of the year are about the fundamental building block of biotechnology, namely, DNA – how to repair it in one case and how to edit it in another. Read More

HONG KONG – New regulations, tighter policies and stronger enforcement in Asia Pacific have increased the risks of fraud in the life science industries and the cost of non-compliance or corruption. Employees in the region are also more conscious of their employers' ethical record. The result is a need for better and sustainable compliance programs for companies operating across Asia Pacific. Read More

NEW DELHI – India cleared two hepatitis C generics drugs within a week, setting the stage for fierce competition between the two Hyderabad-based companies and, possibly, lower prices for much needed drugs. Read More

SHANGHAI – Wuxi Healthcare Ventures closed a fundraising round at $290 million – attracting almost 50 percent more capital than was initially sought – and will now get back to the business of continuing the investment strategy developed with its first fund: find in the U.S, build in China. Read More